Pulse Biosciences (NASDAQ:PLSE) Reaches New 12-Month High – Still a Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE)’s share price reached a new 52-week high on Wednesday . The company traded as high as $31.70 and last traded at $31.7290, with a volume of 69954 shares changing hands. The stock had previously closed at $30.26.

Analyst Upgrades and Downgrades

PLSE has been the topic of several recent research reports. Canaccord Genuity Group assumed coverage on Pulse Biosciences in a research report on Thursday, June 4th. They set a “buy” rating and a $32.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $30.67.

Pulse Biosciences Stock Up 8.6%

The company has a market cap of $2.27 billion, a PE ratio of -29.73 and a beta of 1.65. The stock has a 50-day moving average of $26.39 and a 200-day moving average of $21.78.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Monday, May 4th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.05. The business had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.25 million. Research analysts expect that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Insider Transactions at Pulse Biosciences

In other Pulse Biosciences news, CEO Paul A. Laviolette purchased 15,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $19.69 per share, for a total transaction of $295,350.00. Following the transaction, the chief executive officer owned 15,000 shares in the company, valued at $295,350. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Robert W. Duggan acquired 660,233 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $19.69 per share, with a total value of $12,999,987.77. Following the acquisition, the director directly owned 48,211,433 shares of the company’s stock, valued at $949,283,115.77. This represents a 1.39% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 74.00% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Argo Wealth Advisory LLC purchased a new stake in shares of Pulse Biosciences during the 4th quarter valued at $387,000. Tudor Investment Corp ET AL bought a new stake in shares of Pulse Biosciences during the 4th quarter worth $382,000. Barclays PLC grew its position in Pulse Biosciences by 8.5% in the fourth quarter. Barclays PLC now owns 27,652 shares of the company’s stock worth $380,000 after acquiring an additional 2,164 shares in the last quarter. Alliancebernstein L.P. increased its stake in Pulse Biosciences by 6.7% in the third quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock valued at $365,000 after acquiring an additional 1,300 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in Pulse Biosciences during the first quarter valued at about $323,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.